

32. The liquid pharmaceutical composition of claim 1 wherein the composition contains up to 100 mg/ml of amino acid.

33. The liquid pharmaceutical composition of claim 28, wherein the composition contains 0.05-0.5 mg/ml of surfactant.

34. A liquid pharmaceutical composition comprising the lyophilizate of claim 27 dissolved in a physiologically acceptable solution.

35. The liquid pharmaceutical composition of claim 30, wherein the composition has a pH value of 5-8.


36. A method of preparing a lyophilizate, the method comprising mixing a buffered solution containing a monoclonal antibody or a polyclonal antibody, a sugar or an amino sugar, at least one amino acid and a surfactant, to prepare a mixed solution, wherein the mixed solution has a pH value of 5-8; and lyophilizing the mixed solution.

#### REMARKS

The above amendment to the claims has been made to correct the multiple dependency of the claims and to put the application in better condition for examination.

In the event that any fees are due in connection with this paper, please charge our Deposit Account No. 14-1060.

Respectfully submitted,  
NIKAIDO, MARMELESTEIN, MURRAY & ORAM LLP

  
Richard J. Berman  
Attorney for Applicants  
Reg. No. 39,107

Atty. Docket No.: P8341-9011  
Metropolitan Square  
655 15th Street, N. W.  
Suite 330 - G Street Lobby  
Washington, D. C. 20005-5701  
Tel (202) 638-5000  
Fax (202) 638-4810  
RJB/cb